Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
XAIR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

3.3

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

39.6

EPS This/Next Y

15.6

Price

5.48

Target Price

190

Analyst Recom

1.67

Performance Q

-46.1

Upside

-21,482.1%

Beta

0.17

Ticker: XAIR




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-13XAIR7.43N/AN/A0
2026-07-14XAIR5.86N/AN/A0
2026-07-15XAIR5.59N/AN/A0
2026-07-16XAIR5.45N/AN/A0
2026-07-17XAIR5.705N/AN/A0
2026-07-20XAIR5.9N/AN/A0
2026-07-21XAIR5.86N/AN/A0
2026-07-22XAIR5.83N/AN/A0
2026-07-23XAIR5.4N/AN/A0
2026-07-24XAIR5.2N/AN/A0
2026-07-27XAIR5.37N/AN/A0
2026-07-28XAIR5.53N/AN/A0
2026-07-29XAIR5.5N/AN/A0
2026-07-30XAIR5.37N/AN/A0
2026-07-31XAIR5.34N/AN/A0
2026-08-03XAIR6.33N/AN/A0
2026-08-04XAIR6.21N/AN/A0
2026-08-05XAIR5.69N/AN/A0
2026-08-07XAIR5.63N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-13XAIR7.41- - -2.03
2026-07-14XAIR5.82- - -2.03
2026-07-15XAIR5.61- - -2.03
2026-07-16XAIR5.55- - -2.03
2026-07-17XAIR5.55- - -40.60
2026-07-20XAIR5.90- - -40.60
2026-07-21XAIR5.93- - -40.60
2026-07-22XAIR5.85- - -40.60
2026-07-23XAIR5.53- - -40.60
2026-07-24XAIR5.20- - -40.60
2026-07-27XAIR5.16- - -40.60
2026-07-28XAIR5.58- - -40.60
2026-07-29XAIR5.50- - -40.60
2026-07-30XAIR5.54- - -40.60
2026-07-31XAIR5.30- - -40.60
2026-08-03XAIR6.33- - -40.60
2026-08-04XAIR6.33- - -40.60
2026-08-05XAIR5.66- - -40.60
2026-08-06XAIR5.66- - -40.60
2026-08-07XAIR5.48- - -40.60
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-13XAIR0.00-0.902.36
2026-07-14XAIR0.00-0.902.36
2026-07-15XAIR0.00-0.902.37
2026-07-16XAIR0.00-0.902.34
2026-07-17XAIR0.00-0.902.34
2026-07-20XAIR0.0002.34
2026-07-21XAIR0.0002.55
2026-07-22XAIR0.0002.55
2026-07-23XAIR0.0002.55
2026-07-24XAIR0.0002.55
2026-07-27XAIR0.0003.30
2026-07-28XAIR0.0003.30
2026-07-29XAIR0.0003.30
2026-07-30XAIR0.0003.30
2026-07-31XAIR0.0003.30
2026-08-03XAIR124.7203.30
2026-08-04XAIR124.7203.30
2026-08-05XAIR124.7203.30
2026-08-06XAIR124.8503.30
2026-08-07XAIR124.6503.30
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-10.8

Avg. EPS Est. Next Quarter

-10.2

Insider Transactions

124.65

Institutional Transactions

Beta

0.17

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

17

Growth Score

49

Sentiment Score

72

Actual DrawDown %

99.9

Max Drawdown 5-Year %

-99.9

Target Price

190

P/E

Forward P/E

PEG

P/S

0.5

P/B

0.52

P/Free Cash Flow

EPS

-88.16

Average EPS Est. Cur. Y​

-40.6

EPS Next Y. (Est.)

-25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-432.99

Relative Volume

0.53

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

XAIR Healthcare
$5.36
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
15/25
Volume
11/15
Valuation
12/20
TP/AR
5/10
Options
0/10
RSI
37.1
Range 1M
14.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
17 /100
WEAK
Momentum
0/25
Growth
10/30
Estimates
7/20
Inst/Vol
0/15
Options
0/10
EPS Yr
0%
EPS NY
0%
52W%
0.7%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +3444.8% upside
Quality
2/30
Valuation
16/30
Growth
7/25
Stability
3/10
LT Trend
1/5
Upside
+3444.8%
Quality
17
XAIR — P/E HistoricalMedical Devices
Beyond Air, Inc.
Sector: Healthcare
Industry: Medical Devices
Employees: 54
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
XAIR

Latest News

Caricamento notizie per XAIR
stock quote shares XAIR – Beyond Air Inc Stock Price stock today
news today XAIR – Beyond Air Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch XAIR – Beyond Air Inc yahoo finance google finance
stock history XAIR – Beyond Air Inc invest stock market
stock prices XAIR premarket after hours
ticker XAIR fair value insiders trading